Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Holdings Increased by XTX Topco Ltd

XTX Topco Ltd boosted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 1,104.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 552,613 shares of the biotechnology company’s stock after buying an additional 506,732 shares during the quarter. XTX Topco Ltd owned approximately 0.34% of Ironwood Pharmaceuticals worth $812,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IRWD. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $36,000. Simplicity Wealth LLC acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at approximately $45,000. Envestnet Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $50,000. Boothbay Fund Management LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $57,000. Finally, Y Intercept Hong Kong Ltd boosted its stake in Ironwood Pharmaceuticals by 162.6% in the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 24,635 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Citizens Jmp downgraded Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 14th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.70 price target (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Leerink Partners cut their price target on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating on the stock in a report on Monday, April 14th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $1.00 price target (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus price target of $4.78.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD opened at $0.77 on Monday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $0.53 and a 12 month high of $6.57. The stock has a market cap of $124.83 million, a price-to-earnings ratio of -3.86 and a beta of 0.33. The stock’s 50 day moving average price is $0.72 and its 200 day moving average price is $1.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 1.87% and a negative net margin of 9.89%. The firm had revenue of $41.14 million for the quarter, compared to the consensus estimate of $67.02 million. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.